Semaglutide Associated with Reduced Fracture Risk in Type 2 Diabetes Patients

Semaglutide was linked to a 15% lower risk of fractures among adults with type 2 diabetes, according to a review of medical records.

A matched analysis of over 35,000 patients showed that fracture incidence was 4.54% among semaglutide users during approximately 3.5 years of follow-up, compared with 5.97% among patients using other diabetes or obesity medications (hazard ratio 0.85, 95% CI 0.77-0.93, P<0.001), according to Sun Kim, MD, of Stanford University School of Medicine.

Kim described the results as reassuring, though she expressed enthusiasm at the prospect of these medications providing true bone protection, during a presentation at ENDO 2026, the annual meeting of the Endocrine Society.

Semaglutide users also experienced greater annual reductions in body mass index (BMI) than the control group, with a mean 1‑year BMI decrease of 0.72 (P<0.001), a difference that encompassed patients treated with the GLP-1 agonist dulaglutide (Trulicity) or the weight‑loss agents phentermine‑topiramate (Qsymia) or bupropion‑naltrexone (Contrave).

According to Kim, patients with type 2 diabetes have an elevated fracture risk despite often normal or high bone mineral density, and weight loss — a core treatment objective — usually causes bone loss through mechanical unloading.

She noted several potential contributors to this risk, including diabetes medications that may cause hypoglycemia and increase fall risk, hyperglycemia driven by advanced glycation end‑product accumulation, and chronic inflammation.

These findings suggest that semaglutide may confer an unexpected, inherent benefit for bone health, though further investigation is needed to determine whether this effect is specific to semaglutide or also seen with other GLP‑1 agents, such as the dual GLP‑1/GIP receptor agonist tirzepatide (Mounjaro, Zepbound).

“There is interest in whether the GIP component can also exert additional bone‑protective effects,” she said.

Several prior studies have hinted at a possible bone‑protective effect of GLP‑1 receptor agonists, including a recent observational study examining 10‑year vertebral fracture risk and another study focusing on older women with diabetes.

Kim’s team previously reported that semaglutide users, regardless of diabetes status, had a 26% lower fracture risk compared with sleeve gastrectomy patients over three years; however, because bariatric surgery patients experience markedly greater weight loss, the team considered whether this discrepancy could confound the results, prompting the present study.

This work represents an important early step toward understanding how semaglutide‑induced weight loss affects bone health in type 2 diabetes patients, said co‑author Jairo Noreña Velasquez, MD, of Stanford University Medical Center.

“Bone fractures are painful, costly, and can markedly diminish quality of life — particularly in older adults,” he added. “We hope this study promotes routine monitoring of bone health within weight‑loss programs.”

The analysis utilized the Atropos Health Eos electronic health record dataset from U.S. community hospitals and academic medical centers between January 2016 and December 2023. Inclusion criteria required a type 2 diabetes diagnosis without prior fracture or osteoporosis medication use, and treatment with one of the study drugs within one year of diabetes diagnosis, followed by a second refill 9–15 months later.

The mean patient age was 54 years; the majority were women (54–55%) and white (54%); mean BMI was 38; average comorbidity score was 3, and approximately 15% of participants had diabetes with complications.

Source link